1.Matsuoka K, Kobayashi T, Ueno F, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53(3):305–353.
2.Gomollon F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: Diagnosis and medical management. J Crohns Colitis. 2017;11(1):3–25.
3.Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113(4):481–517.
4.Ueno F, Nakayama Y, Hagiwara E, et al. Impact of inflammatory bowel disease on Japanese patients’ quality of life: results of a patient questionnaire survey. J Gastroenterol. 2017;52(5):555–567.
5.Yamabe K, Liebert R, Flores N, et al. Health-related quality of life outcomes and economic burden of inflammatory bowel disease in Japan. Clinicoecon Outcomes Res. 2019;11:221–232.
6.Murakami Y, Nishiwaki Y, Oba MS, et al. Estimated prevalence of ulcerative colitis and Crohn’s disease in Japan in 2014: an analysis of a nationwide survey. J Gastroenterol. 2019.
7.Japanese Ministry of Health Labour and Welfare. Overview of 2014 Health Administration Reports, Section 7: Specific Diseases (Incurable) [In Japanese].http://www.mhlw.go.jp/toukei/saikin/hw/eisei_houkoku/14/dl/kekka7.pdf (Accessed 14 May 2019)
8.Adegbola SO, Sahnan K, Warusavitarne J, et al. Anti-TNF therapy in Crohn’s disease. Int J Mol Sci. 2018;19(8):E2244.
9.Yanai S, Matsumoto T. Biologic drugs for inflammatory bowel disease. Nihon Rinsho. 2017;75(3):403–407.
10.Japan Medical Data Center. JMDC Claims Database.https://www.jmdc.co.jp/en/pharma/database.html (Accessed 14 May 2019)
11.Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD–9-CM and ICD–10 administrative data. Med Care. 2005;43(11):1130–1139.
12.Yokoyama K, Yamazaki K, Katafuchi M, et al. A retrospective claims database study on drug utilization in Japanese patients with Crohn’s disease treated with adalimumab or infliximab. Adv Ther. 2016;33(11):1947–1963.
13.Asakura K, Nishiwaki Y, Inoue N, et al. Prevalence of ulcerative colitis and Crohn’s disease in Japan. J Gastroenterol. 2009;44(7):659–665.
14.Mahlich J, Matsuoka K, Sruamsiri R. Biologic treatment of Japanese patients with inflammatory bowel disease. BMC Gastroenterol. 2018;18(1):160.
15.Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res. 2016;14(2):111–119.
16.Yao T, Matsui T, Hiwatashi N. Crohn’s disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum. 2000;43(10 Suppl):S85–93.
17.Bokemeyer B, Hardt J, Huppe D, et al. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry. J Crohns Colitis. 2013;7(5):355–368.
18.Bots SJA, Hoekman DR, Benninga MA, et al. Patterns of anti-TNF use and associated treatment outcomes in inflammatory bowel disease patients: results from an analysis of Dutch health insurance claims data. Neth J Med. 2017;75(10):432–442.
19.Burisch J, Kiudelis G, Kupcinskas L, et al. Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut. 2018. doi: 10.1136/gutjnl–2017–315568.
20.Han M, Jung YS, Cheon JH, et al. Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases. J Gastroenterol Hepatol. 2019;34(7):1166–1174.
21.Jung YS, Han M, Kim WH, et al. Incidence and clinical outcomes of inflammatory bowel disease in South Korea, 2011–2014: a nationwide population-based study. Dig Dis Sci. 2017;62(8):2102–2112.
22.Kurti Z, Vegh Z, Golovics PA, et al. Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary: a population-based study based on the National Health Insurance Fund database. Dig Liver Dis. 2016;48(11):1302–1307.
23.Lirhus SS, Hoivik ML, Moum B, et al. Regional differences in anti-TNF-alpha therapy and surgery in the treatment of inflammatory bowel disease patients: a Norwegian nationwide cohort study. Scand J Gastroenterol. 2018;53(8):952–957.
24.Kondo J, Iijima H, Abe T, et al. Roles of double-balloon endoscopy in the diagnosis and treatment of Crohn’s disease: a multicenter experience. J Gastroenterol. 2010;45(7):713–720.
25.Yamamoto H, Ogata H, Matsumoto T, et al. Clinical Practice Guideline for Enteroscopy. Dig Endosc. 2017;29(5):519–546.
26.Brady JE, Stott-Miller M, Mu G, et al. Treatment patterns and sequencing in patients with inflammatory bowel disease. Clin Ther. 2018;40(9):1509–1521.
27.Chen C, Hartzema AG, Xiao H, et al. Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive therapy. Inflamm Bowel Dis. 2019;25(8):1417–1427.
28.Khan S, Rupniewska E, Neighbors M, et al. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019;44(4):495–507.
29.Sartini A, Scaioli E, Liverani E, et al. Retention rate, persistence and safety of adalimumab in inflammatory bowel disease: a real-life, 9-year, single-center experience in Italy. Dig Dis Sci. 2019;64(3):863–874.
30.Holko P, Kawalec P, Pilc A. Impact of biologic treatment of Crohn’s disease on the rate of surgeries and other healthcare resources: an analysis of a nationwide database from Poland. Front Pharmacol. 2018;9:621.
31.Leombruno JP, Nguyen GC, Grootendorst P, et al. Hospitalization and surgical rates in patients with Crohn’s disease treated with infliximab: a matched analysis. Pharmacoepidemiol Drug Saf. 2011;20(8):838–848.
32.Mao EJ, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther. 2017;45(1):3–13.
33.Pentek M, Lakatos PL, Oorsprong T, et al. Access to biologicals in Crohn’s disease in ten European countries. World J Gastroenterol. 2017;23(34):6294–6305.
34.Wright EK, Kamm MA, Dr Cruz P, et al. Cost-effectiveness of Crohn’s disease post-operative care. World J Gastroenterol. 2016;22(14):3860–3868.
35.Yu H, MacIsaac D, Wong JJ, et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment Pharmacol Ther. 2018;47(3):364–370.